These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 9226621)
1. Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. Gamble KC; Alvarado TP; Bennett CL J Zoo Wildl Med; 1997 Mar; 28(1):89-93. PubMed ID: 9226621 [TBL] [Abstract][Full Text] [Related]
2. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe DM; Herring I; Calvin J; Way N; Dvorak J Am J Vet Res; 1997 Aug; 58(8):872-7. PubMed ID: 9256973 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Conway SP; Etherington C; Peckham DG; Brownlee KG; Whitehead A; Cunliffe H J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Boogaerts MA; Maertens J; Van Der Geest R; Bosly A; Michaux JM; Van Hoof A; Cleeren M; Wostenborghs R; De Beule K Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397 [TBL] [Abstract][Full Text] [Related]
5. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Ducharme MP; Slaughter RL; Warbasse LH; Chandrasekar PH; Van de Velde V; Mannens G; Edwards DJ Clin Pharmacol Ther; 1995 Dec; 58(6):617-24. PubMed ID: 8529326 [TBL] [Abstract][Full Text] [Related]
6. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Varis T; Kivistö KT; Backman JT; Neuvonen PJ Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751 [TBL] [Abstract][Full Text] [Related]
7. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral antifungals and their clinical implications. Heykants J; Van Peer A; Lavrijsen K; Meuldermans W; Woestenborghs R; Cauwenbergh G Br J Clin Pract Suppl; 1990 Sep; 71():50-6. PubMed ID: 1965419 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid and blood concentrations of toltrazuril 5% suspension in the horse after oral dosing. Furr M; Kennedy T Vet Ther; 2000; 1(2):125-32. PubMed ID: 19757559 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, blood partition, and tissue distribution of itraconazole. Lee JH; Shin JH; Lee MG Res Commun Mol Pathol Pharmacol; 2004; 115-116():203-15. PubMed ID: 17564318 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fluconazole after oral administration of single and multiple doses in African grey parrots. Flammer K; Papich M Am J Vet Res; 2006 Mar; 67(3):417-22. PubMed ID: 16506902 [TBL] [Abstract][Full Text] [Related]
12. Single dose and multiple dose studies of itraconazole nanoparticles. Vaughn JM; McConville JT; Burgess D; Peters JI; Johnston KP; Talbert RL; Williams RO Eur J Pharm Biopharm; 2006 Jun; 63(2):95-102. PubMed ID: 16516450 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Mouton JW; van Peer A; de Beule K; Van Vliet A; Donnelly JP; Soons PA Antimicrob Agents Chemother; 2006 Dec; 50(12):4096-102. PubMed ID: 16982783 [TBL] [Abstract][Full Text] [Related]
15. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Caillot D; Bassaris H; McGeer A; Arthur C; Prentice HG; Seifert W; De Beule K Clin Infect Dis; 2001 Oct; 33(8):e83-90. PubMed ID: 11550120 [TBL] [Abstract][Full Text] [Related]
16. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Poirier JM; Berlioz F; Isnard F; Cheymol G Therapie; 1996; 51(2):163-7. PubMed ID: 8763051 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Michallet M; Persat F; Kranzhöfer N; Levron JC; Prat C; Belhabri A; Chwetzoff E; Le Moing JP; Fiere D; Piens MA Bone Marrow Transplant; 1998 Jun; 21(12):1239-43. PubMed ID: 9674858 [TBL] [Abstract][Full Text] [Related]
20. Optimisation of itraconazole therapy using target drug concentrations. Poirier JM; Cheymol G Clin Pharmacokinet; 1998 Dec; 35(6):461-73. PubMed ID: 9884817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]